TF Capital
VC Fund
Pudong, China
TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.
- Total investments:
- 63
- Last investment:
- Lead investor:
- 11%
Last updated:
For AI agents: llms.txt
Industries TF Capital invests in
Stages TF Capital invests in
Countries TF Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $10M–$120M
- Series B
- $11M–$110M
- Series C
- $7M–$1.4B
Investment Focus
Industry
- Biotechnology 34 (54%)
- Health Care 29 (46%)
- Medical 21 (33%)
- Pharmaceutical 18 (29%)
- Biopharma 12 (19%)
Stage
- Series A 27 (43%)
- Series B 17 (27%)
- Series C 5 (8%)
- Seed 4 (6%)
- Venture - Series Unknown 4 (6%)
Country
- China 41 (65%)
- United States 10 (16%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dr. Zhang Yibo
Partner
|
Partner | Total investments: 1 | Find email | |
|
H.J. Jiang
Founder & CEO
|
Founder & CEO | Total investments: 1 | Find email | |
|
Wei Cheng
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
Yi Liu
Director
|
Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Vivatides Therapeutics
|
Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research. | $54M / Series A / Apr 10, 2026 | |
| QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases. | $72.8M / Series C / Mar 02, 2026 | ||
| Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $130M / Series D / Feb 05, 2026 | ||
| Skild AI is a startup that develops software to power various robots including ones with two or four legs. | $1.4B / Series C / Jan 14, 2026 | ||
|
Sanegene Bio
|
Sanegene Bio is currently operating in stealth mode. | $110M / Series B / Dec 08, 2025 | |
| Vybio focuses on the research and development of new drugs for oncology and hepatitis B. The core members of the team have 30 years of experience in tumor and hepatitis B drug research and development, and come from well-known pharmaceutical companies such as WuXi AppTec, Pfizer, BMS, etc., using a specific tumor microenvironment to independentlyinnovate prodrug design and screening, and developed a series of global drugs. Preclinical research on precisely targeted small molecule anticancer prodrug compounds protected by intellectual property rights is being carried out in an orderly manner. | $14.1M / Series B / Nov 13, 2025 | ||
|
Huanxin Medical
|
Huanxin Medical is an innovative medical device company that specializes in the research and development of interventional medical devices. | Series B / Aug 14, 2025 | |
| Minghui Pharmaceutical is a biopharmaceutical business that specializes in immunology and oncology medicines for unmet needs. | $131M / Venture - Series Unknown / Aug 07, 2025 | ||
| Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $50M / Series A / Nov 18, 2024 | ||
| Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment. | $150M / Series A / Mar 26, 2024 | ||
| See all 63 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does TF Capital invest in?
TF Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 63 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does TF Capital invest in?
TF Capital typically joins rounds of $10M–$120M at Series A, $11M–$110M at Series B and $7M–$1.4B at Series C. These are whole funding-round sizes, not TF Capital's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds TF Capital took part in.
How do I contact TF Capital?
Public channels for TF Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TF Capital?
The team at TF Capital includes Dr. Zhang Yibo (Partner), H.J. Jiang (Founder & CEO) and Wei Cheng (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
